Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis
Abstract
Background Allergic bronchopulmonary aspergillosis (ABPA) is a complex allergic hypersensitivity reaction to Aspergillus species that can complicate and worsen concomitant asthma and is associated with an intense type 2 immune response in lower airways; there are no approved targeted therapies. Objective To investigate dupilumab, a fully human monoclonal antibody blocking interleukins 4/13 via the shared interleukin 4 receptor alpha, in patients with asthma and ABPA. Methods In this double-blind phase 2 trial, patients with asthma aged ≥12 years who met the clinical criteria for ABPA were randomized to dupilumab (n=35) or placebo (n=27) for 24 to 52 weeks; 37.1% were receiving chronic systemic corticosteroids (SCS). The primary endpoint was change from baseline in prebronchodilator forced expiratory volume in 1 second (FEV 1 ) at 24 weeks. Additional endpoints included severe respiratory exacerbations and SCS use. Results At week 24, prebronchodilator FEV 1 was significantly improved with dupilumab versus placebo (least squares mean change, 0.203 L vs 0.002 L; least squares mean treatment difference, 0.201 L; 95% confidence interval [CI], 0.08-0.33; P =0.002). The adjusted annualized severe respiratory exacerbation rate per person-year was 0.695 (95% CI, 0.35-1.36) with dupilumab and 1.551 (95% CI, 0.75-3.22) with placebo, a 55.2% reduction; nominal P =0.0627. At week 24, 71.4% of dupilumab recipients who required SCS at baseline no longer required SCS, compared with 14.3% receiving placebo. Overall safety was consistent with the known dupilumab safety profile. Conclusions In patients with asthma and ABPA, dupilumab significantly improved lung function compared with placebo, reduced severe respiratory exacerbations, and was well tolerated.
Related
- Treatment Impact on Inflammatory Markers in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis
- Longitudinal changes in type 2 and Aspergillus-specific biomarkers during omalizumab therapy for allergic bronchopulmonary aspergillosis: a 36-week study in Chinese patients
- Advances in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis/Mycosis.
- The efficacy and safety of dupilumab therapy in pediatric patients with refractory eosinophilic duodenal bulb ulcer: a retrospective cohort study
- Antimicrobial Resistance-Stratified Efficacy of Vonoprazan, Clarithromycin, and Metronidazole Therapy for Helicobacter pylori Eradication in Penicillin-Allergic Patients: A Single-Arm Prospective Interventional Study.
BibTeX
@article{bourdin2026dupilumab,
title = {{Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis}},
author = {Arnaud Bourdin and Jonathan Corren and Anand Shah and Caroline Baxter and Lavinia Davidescu and Heather Paleczny and Joseph Chiarappa and Andrew Fontenot and Paula Dakin and Elizabeth Laws and Jennifer Maloney and Lacey Robinson and George Yancopoulos and Allen Radin},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
month = sep,
doi = {10.1016/j.jaci.2026.08.021},
url = {https://hal.science/hal-05739745v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Dupilumab efficacy and safety in patients with allergic bronchopulmonary aspergillosis
AU - Arnaud Bourdin
AU - Jonathan Corren
AU - Anand Shah
AU - Caroline Baxter
AU - Lavinia Davidescu
AU - Heather Paleczny
AU - Joseph Chiarappa
AU - Andrew Fontenot
AU - Paula Dakin
AU - Elizabeth Laws
AU - Jennifer Maloney
AU - Lacey Robinson
AU - George Yancopoulos
AU - Allen Radin
PY - 2026
DA - 2026/09/05
JO - Journal of Allergy and Clinical Immunology
DO - 10.1016/j.jaci.2026.08.021
UR - https://hal.science/hal-05739745v1
AB - Background Allergic bronchopulmonary aspergillosis (ABPA) is a complex allergic hypersensitivity reaction to Aspergillus species that can complicate and worsen concomitant asthma and is associated with an intense type 2 immune response in lower airways; there are no approved targeted therapies. Objective To investigate dupilumab, a fully human monoclonal antibody blocking interleukins 4/13 via the shared interleukin 4 receptor alpha, in patients with asthma and ABPA. Methods In this double-blind phase 2 trial, patients with asthma aged ≥12 years who met the clinical criteria for ABPA were randomized to dupilumab (n=35) or placebo (n=27) for 24 to 52 weeks; 37.1% were receiving chronic systemic corticosteroids (SCS). The primary endpoint was change from baseline in prebronchodilator forced expiratory volume in 1 second (FEV 1 ) at 24 weeks. Additional endpoints included severe respiratory exacerbations and SCS use. Results At week 24, prebronchodilator FEV 1 was significantly improved with dupilumab versus placebo (least squares mean change, 0.203 L vs 0.002 L; least squares mean treatment difference, 0.201 L; 95% confidence interval [CI], 0.08-0.33; P =0.002). The adjusted annualized severe respiratory exacerbation rate per person-year was 0.695 (95% CI, 0.35-1.36) with dupilumab and 1.551 (95% CI, 0.75-3.22) with placebo, a 55.2% reduction; nominal P =0.0627. At week 24, 71.4% of dupilumab recipients who required SCS at baseline no longer required SCS, compared with 14.3% receiving placebo. Overall safety was consistent with the known dupilumab safety profile. Conclusions In patients with asthma and ABPA, dupilumab significantly improved lung function compared with placebo, reduced severe respiratory exacerbations, and was well tolerated.
SN - 0091-6749
ER -